Voluntary disclosure announcement regarding the acceptance of the marketing application for Telicibumab Injection for adult seasonal allergic rhinitis indications
Securities code: 688443 Securities abbreviation: Zhixiang Jintai Announcement number: 2026-009
Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Recently, the Phase III clinical trial of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s Telicibumab Injection (GR1802 Injection) for the indication of seasonal allergic rhinitis in adults has reached the primary endpoint. The company submitted a new drug marketing application for this indication to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and was accepted.
1. Basic information on drugs
Drug name: Telicibizumab injection
Application matters: Registration and marketing authorization for domestically produced drugs
Applicant: Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Acceptance number: CXSS2600031
Approval conclusion: According to the provisions of Article 32 of the "Administrative Licensing Law of the People's Republic of China", after review, it is decided to accept the application.
2. Other related information about drugs
Telicibizumab injection (GR1802 injection) is a recombinant fully human anti-IL-4Rα monoclonal antibody independently developed by the company, and its target is IL-4Rα. Telicibizumab injection can specifically bind to human IL-4Rα on the cell surface, block the binding of IL-4, IL-13 and IL-4Rα, inhibit downstream STAT6 phosphorylation, inhibit CD23 upregulation, thereby inhibiting Th2-type inflammatory responses mediated by IL-4 or IL-13.
The new drug marketing application for Telicibizumab Injection (GR1802 Injection) for the indication of moderate and severe atopic dermatitis in adults has been accepted in September 2025. There are several other indications in the clinical trial stage. The indications for chronic sinusitis with nasal polyps, chronic spontaneous urticaria, seasonal allergic rhinitis in adolescents are in the Phase III clinical trial stage, and the asthma indication is in the Phase II clinical trial stage. Phase Ib/IIa clinical trials for atopic dermatitis indications in children/adolescents.
As of the date of this announcement, only two drugs with the same target as Telicibumab Injection (GR1802 Injection) have been approved for marketing in China.
3. Risk warning
According to the requirements of laws and regulations related to national drug registration, new drug marketing applications still need to go through review, drug clinical trial on-site inspection, drug production on-site inspection and approval, etc. There is uncertainty about whether the product can be successfully launched and when it will be launched.
The company will promptly perform information disclosure obligations on subsequent progress in accordance with relevant regulations. Investors are advised to make prudent decisions and pay attention to preventing investment risks.
Announcement is hereby made.
Board of Directors of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
February 27, 2026